PRECLINICAL IN VITRO AND IN VIVO PROFILE OF PXT3003, A NEW PROMISING THERAPEUTIC CANDIDATE FOR CMT1A

被引：0
|
作者：
Chumakov, I [1 ]
Nabirotchkin, S. [1 ]
Milet, A. [1 ]
Cholet, N. [1 ]
Primas, G. [1 ]
Graudens, E. [1 ]
Bertrand, V [1 ]
Mandel, J. [1 ]
Pereira, Y. [1 ]
Nave, K-A [2 ]
Guerassimenko, O. [1 ]
Vial, E. [1 ]
Guedj, M. [1 ]
Cohen, D. [1 ]
机构：
[1] Pharnext, Issy Les Moulineaux, France
[2] Max Planck Inst, Gottingen, Germany
来源：
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM | 2013年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：23 / 23
页数：1
相关论文
共 50 条
  • [1] BASELINE ANALYSIS OF PXT3003 PHASE 2 DATA REVEALS TWO BLOOD EARLY CANDIDATE BIOMARKERS FOR THERAPEUTIC RESPONSE IN CMT1A
    Laffaire, J.
    Mandel, J.
    Bertrand, V
    Scart-Gres, C.
    Milet, A.
    Hajj, R.
    Chumakov, I
    Nabirotchkin, S.
    Guedj, M.
    Cohen, D.
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2015, 20 (02) : 177 - 177
  • [2] Baclofen, naltrexone and sorbitol all contribute to the efficacy of PXT3003 in CMT1A rats
    Hajj, R.
    Prukop, T.
    Wernick, S.
    Ewers, D.
    Brureau, A.
    Laffaire, J.
    Cholet, N.
    Nave, K-A.
    Cohen, D.
    Sereda, M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 542 - 542
  • [3] Baclofen, naltrexone and sorbitol all contribute to the efficacy of PXT3003 in CMT1A rats
    Hajj, Rodolphe
    Prukop, Thomas
    Wernick, Stephanie
    Ewers, David
    Brureau, Anthony
    Laffaire, Julien
    Cholet, Nathalie
    Nave, Klaus-Armin
    Hajj, Rodolphe
    Cohen, Daniel
    Sereda, Michael
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2018, 23 (04) : 258 - 258
  • [4] PXT3003 induces myelination by improving energy metabolism and degradation pathways altered in CMT1A
    Boussicault, Lydie
    Callizot, Noelle
    Nabirotchkin, Serguei
    Hajj, Rodolphe
    Cohen, Daniel
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2020, 25 (04) : 442 - 442
  • [5] Synergy of baclofen, naltrexone and sorbitol (PXT3003) in Charcot-Marie-Tooth Type 1A (CMT1A)
    Laffaire, Julien
    Rinaudo, Philippe
    Bertrand, Viviane
    Schmitt, Peter
    Goedkoop, Rene
    Cohen, Daniel
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2018, 23 (04) : 335 - 335
  • [6] Status of the pivotal phase III study of PXT3003 for Charcot-Marie-Tooth Type 1A disease (CMT1A)
    Goedkoop, Rene
    Attarian, Sharam
    Young, Peter
    Sevilla, Teresa
    Van Damme, Philip
    de Visser, Marianne
    Thomas, Florian
    Roberts, Mark
    Foucquier, Julie
    Boutalbi, Youcef
    Cohen, Daniel
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2018, 23 (04) : 319 - 319
  • [7] AN EXPERIMENTAL TRIAL OF AN EARLY ONSET TREATMENT WITH A COMBINATIONAL DRUG (PXT3003) CONSISTING OF BACLOFEN, NALTREXONE AND SORBITOL IN THE CMT1A RAT MODEL
    Prukop, T.
    Milet, A.
    Stenzel, J.
    Cholet, N.
    Nabirotchkin, S.
    Hajj, R.
    Nave, K-A
    Chumakov, I
    Cohen, D.
    Sereda, M. W.
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2015, 20 (02) : 213 - 213
  • [8] A COMBINATION OF THREE REPURPOSED DRUGS (PXT3003) SYNERGISTICALLY INCREASES MYELINATION IN CO-CULTURES OF SCHWANN CELLS AND NEURONS DERIVED FROM CMT1A RATS
    Cholet, N.
    Laffaire, J.
    Guedj, M.
    Murphy, P. N.
    Chumakov, I
    Nabirotchkin, S.
    Hajj, R.
    Cohen, D.
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2017, 22 (03) : 260 - 260
  • [9] Synergistic PXT3003 therapy uncouples neuromuscular function from dysmyelination in male Charcot-Marie-Tooth disease type 1A (CMT1A) rats
    Prukop, Thomas
    Wernick, Stephanie
    Boussicault, Lydie
    Ewers, David
    Jaeger, Karoline
    Adam, Julia
    Winter, Lorenz
    Quintes, Susanne
    Linhoff, Lisa
    Barrantes-Freer, Alonso
    Bartl, Michael
    Czesnik, Dirk
    Zschuentzsch, Jana
    Schmidt, Jens
    Primas, Gwenael
    Laffaire, Julien
    Rinaudo, Philippe
    Brureau, Anthony
    Nabirotchkin, Serguei
    Schwab, Markus H.
    Nave, Klaus-Armin
    Hajj, Rodolphe
    Cohen, Daniel
    Sereda, Michael W.
    JOURNAL OF NEUROSCIENCE RESEARCH, 2020, 98 (10) : 1933 - 1952
  • [10] A PHASE II RANDOMIZED, PLACEBO-CONTROLLED MULTICENTER CLINICAL TRIAL OF THREE DOSES OF PXT3003 IN 80 ADULT PATIENTS WITH CMT1A TREATED FOR 1 YEAR
    Attarian, S.
    Dubourg, O.
    Funalot, B.
    Gonnaud, P-M
    Lacour, A.
    Magy, L.
    Micallef, J.
    Pereon, Y.
    Pouget, J.
    Stojkovic, T.
    Vallat, J-M
    Nave, K-A
    Bertrand, V
    Cholet, N.
    Graudens, E.
    Guerassimenko, O.
    Milet, A.
    Mandel, J.
    Gres, Scart C.
    Vial, E.
    Guedj, M.
    Nabirotchkin, S.
    Chumakov, I
    Cohen, D.
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2013, 18 : 7 - 8
12345